STOCK TITAN

Canton Strategic Holdings (CNTN) Stock Price, News & Analysis

CNTN NASDAQ

Company Description

Canton Strategic Holdings, Inc. (NASDAQ: CNTN) is an operating company focused on Canton Coin, Canton Network infrastructure and clinical-stage biotechnology research and development. The company describes itself as the first publicly traded company to leverage Canton Coin to support the Canton Network's role in digitizing traditional financial markets. Its digital asset strategy centers on Canton Coin acquisition, operation of a Super Validator, participation in network governance and investment in applications that support Canton Network utilization.

The Canton Network is a privacy-enabled blockchain architecture used for institutional financial-market activity. Canton Strategic Holdings participates in that ecosystem through validator operations that support transaction validation and network operations. The company also maintains a Canton-focused digital asset treasury strategy and has arranged regulated custody and operational controls for its digital asset holdings, including cold storage and multi-signature wallet infrastructure.

Digital asset and network activities

The company's Canton Network activities are built around Canton Coin, validator infrastructure and applications intended to expand network use by institutional market participants. Canton Strategic Holdings also participates in Canton Foundation governance. The Canton Foundation is described in company materials as the independent governance body responsible for the operation, standards and validator framework of the Canton Network, including policies related to the Global Synchronizer and broader network operations.

Canton Strategic Holdings established its digital asset strategy through a completed private placement in 2025. Its public disclosures describe this strategy as including Canton Coin acquisition, Super Validator operations, investments in applications that support network utilization and governance participation through the Canton Foundation.

Biotechnology research and development

In addition to its digital asset activities, Canton Strategic Holdings operates a clinical-stage biotechnology research and development arm. The biotech business includes GV104, identified as a flagship clinical asset being developed for respiratory and/or nervous system depression in military personnel and chemical incident responders. The pipeline also includes other potential GV104 indications, GV023 for autoimmune disease approaches and an early-stage multispecific biologic platform.

Canton Strategic Holdings is listed on Nasdaq under the symbol CNTN. Its principal executive offices are in Red Bank, New Jersey.

Stock Performance

$2.06
+1.72%
+0.04
Last updated: July 28, 2026 at 11:41
-
Performance 1 year
$149.6M

Canton Strategic Holdings (CNTN) stock last closed at $2.03. At a market capitalization of $149.6M, CNTN is classified as a micro-cap stock with approximately 77.1M shares outstanding.

See what a $1,000 investment in CNTN would be worth today

Latest News

Canton Strategic Holdings has 10 recent news articles, with the latest published today. Of the recent coverage, 5 articles coincided with positive price movement and 4 with negative movement. Key topics include management, buybacks, earnings. View all CNTN news →

SEC Filings

Canton Strategic Holdings has filed 5 recent SEC filings, including 3 Form 3, 2 Form 8-K. The most recent filing was submitted on July 23, 2026. SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all CNTN SEC filings →

Insider Radar

Net Sellers
90-Day Summary
0
Shares Bought
100,351
Shares Sold
8
Transactions
Most Recent Transaction
Stetz Gary S. (Director) sold 12,500 shares @ $3.47 on May 26, 2026

Insider selling at Canton Strategic Holdings over the past 90 days can reflect routine portfolio management, scheduled trading plans (Rule 10b5-1), tax planning, or compensation-related dispositions rather than a directional view on the stock.

Based on SEC Form 4 filings over the last 90 days.

Financial Highlights

operating income reached -$20.1M, and net income was -$35.9M. Diluted earnings per share stood at $-1.12. The company generated -$16.1M in operating cash flow. With a current ratio of 5.29, the balance sheet reflects a strong liquidity position.

-$35.9M
Net Income (FY2025)
-$16.1M
Operating Cash Flow
Revenue (FY2025)

Upcoming Events

Short Interest History

Last 12 Months

Short interest in Canton Strategic Holdings (CNTN) currently stands at 7.8 million shares, up 11.4% from the previous reporting period, representing 12.4% of the float. Since February 2026, short interest has increased by 167.5%. This moderate level of short interest indicates notable bearish positioning. With 11.8 days to cover, it would take significant time for short sellers to close their positions based on average trading volume.

Days to Cover History

Last 12 Months

Days to cover for Canton Strategic Holdings (CNTN) currently stands at 11.8 days, up 227.1% from the previous period. This elevated days-to-cover ratio indicates it would take over two weeks of average trading volume for short sellers to exit their positions, suggesting potential for a short squeeze if positive news emerges. The days to cover has increased 172.8% over the past year, indicating either rising short interest or declining trading volume. The ratio has shown significant volatility over the period, ranging from 3.6 to 11.8 days.

CNTN Company Profile & Sector Positioning

Canton Strategic Holdings (CNTN) operates in the Biotechnology industry within the broader Pharmaceutical Preparations sector and is listed on the NASDAQ. In monthly performance, the stock ranks #3,759 among all tracked companies.

Frequently Asked Questions

What is the current stock price of Canton Strategic Holdings (CNTN)?

The current stock price of Canton Strategic Holdings (CNTN) is $2.03 as of July 27, 2026.

What is the market cap of Canton Strategic Holdings (CNTN)?

The market cap of Canton Strategic Holdings (CNTN) is approximately 149.6M. Learn more about what market capitalization means .

What is the net income of Canton Strategic Holdings (CNTN)?

The FY2025 net income of Canton Strategic Holdings (CNTN) is -$35.9M, from its most recent completed fiscal year.

What is the earnings per share (EPS) of Canton Strategic Holdings (CNTN)?

The diluted earnings per share (EPS) of Canton Strategic Holdings (CNTN) is $-1.12 for FY2025, its most recent completed fiscal year. Learn more about EPS .

What is the operating cash flow of Canton Strategic Holdings (CNTN)?

The operating cash flow of Canton Strategic Holdings (CNTN) is -$16.1M. Learn about cash flow.

What is the current ratio of Canton Strategic Holdings (CNTN)?

The current ratio of Canton Strategic Holdings (CNTN) is 5.29, indicating the company's ability to pay short-term obligations. Learn about liquidity ratios.

What is the operating income of Canton Strategic Holdings (CNTN)?

The operating income of Canton Strategic Holdings (CNTN) is -$20.1M. Learn about operating income.

What does Canton Strategic Holdings do?

Canton Strategic Holdings operates a digital asset strategy tied to Canton Coin and the Canton Network, and it also operates a clinical-stage biotechnology research and development arm.

How does Canton Strategic Holdings participate in the Canton Network?

The company participates through Canton Coin activities, operation of a Super Validator, validator-related network operations, governance participation and investment in applications that support network utilization.

What is Canton Coin's role in the company's strategy?

Canton Coin is central to Canton Strategic Holdings' digital asset strategy. The company describes its strategy as including Canton Coin acquisition and activities that support the Canton Network's use in institutional financial-market digitization.

Does Canton Strategic Holdings operate a validator node?

Yes. Company materials describe Canton Strategic Holdings as operating validator infrastructure, including a Super Validator role and a validator node that supports transaction validation and network operations on the Canton Network.

Does Canton Strategic Holdings have biotechnology operations?

Yes. The company operates a clinical-stage biotechnology research and development arm alongside its Canton Network and digital asset activities.

What biotechnology assets are associated with Canton Strategic Holdings?

The biotech arm includes GV104, a clinical asset being developed for respiratory and/or nervous system depression in military personnel and chemical incident responders. The pipeline also references additional GV104 indications, GV023 and an early-stage multispecific biologic platform.

What is the company's relationship with the Canton Foundation?

Canton Strategic Holdings is a member of the Canton Foundation. Company disclosures describe the Foundation as the governance body responsible for Canton Network operations, standards and validator framework matters.

Where is Canton Strategic Holdings listed and headquartered?

Canton Strategic Holdings is listed on Nasdaq under the symbol CNTN. Its principal executive offices are in Red Bank, New Jersey.